TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* No current or prior anti-HIV treatment, including ART medications received for prevention (preexposure prophylaxis \[PrEP\]), or postexposure prophylaxis (PEP) within 12 weeks of screening~* Plasma HIV-1 ribonucleic acid (RNA) ≥ 10,000 copies/mL but ≤ 400,000 copies/mL at screening~* Cluster of differentiation 4+ (CD4+) cell count \> 200 cells/mm\^3~Key Exclusion Criteria:~* Anticipated to start HIV-1 therapy during the study period~* Active participation in another study of investigational or approved ART agents~* A new acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within the 30 days prior to screening~* Participants with positive hepatitis C antibody at screening~* Chronic hepatitis B virus (HBV) infection~* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 42 days prior to Day 1 (baseline)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Bictegravir 5 mg (Type: EXPERIMENTAL): Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
- Bictegravir 25 mg (Type: EXPERIMENTAL): Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
- Bictegravir 50 mg (Type: EXPERIMENTAL): Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
- Bictegravir 100 mg (Type: EXPERIMENTAL): Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to bictegravir tablet for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children presenting at one of the health centres in the study area~* Symptoms suggestive of malaria~* At least 20 P.falciparum parasites per 200 leucocytes~* Living in the study area (to enable follow-up)~Exclusion Criteria:~* Danger signs~* By the responsible doctor evaluated to need to be transferred to the national hospital as an in-patient~* Previous idiosyncratic reactions to any of the study drugs

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1 Coartem (Type: EXPERIMENTAL): Treatment of documented malaria in children following the dosages recommended by the manufacturer.
- 2 Chloroquine (Type: ACTIVE_COMPARATOR): The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Amphotericin in Disseminated Leishmaniasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* a) clinical diagnosis of Disseminated Leishmaniasis according to case definition; b) illness duration of less than three months, c) parasite identification by culture or polymerase chain reaction methods, d) no previous treatment for leishmaniasis.~Exclusion Criteria:~* a) immunodeficiency or antibodies to HIV, b) pregnancy or patients not willing or unable to use contraceptives during and 3 months after the end of therapy c) ALT, AST ≥3x normal reference values, creatinine and BUN ≥1.5x normal reference values, d) any evidence of serious underlying disease (cardiac, renal, hepatic, or pulmonary) including serious infection other than DL.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Liposomal Amphotericin (Type: EXPERIMENTAL): Liposomal Amphotericin by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of panic disorder, with or without agoraphobia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, text revision (DSM-IV-TR) criteria, as determined by a structured clinical interview.~* At least two panic attacks in the week preceding their inclusion in the study.~Exclusion Criteria:~* Patients unable or unwilling to provide written informed consent.~* Did not complete all the evaluations before study initiation.~* Had comorbidities that could affect clinical evaluation including drug abuse, neurological disorders, or severe personality disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Clonazepam (Type: ACTIVE_COMPARATOR): Treatment with clonazepam
- Paroxetine (Type: ACTIVE_COMPARATOR): Treatment with paroxetine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 18 years of age or older with normal skin~* Have used no topical medications on the skin of the upper extremities, except for emollients or sunscreens, for at least 30 days prior to study entry~* Agree to limit sun exposure as much as possible and wear protective clothing on the forearms in place of using sunscreens or moisturizers~* Ability to understand and willingness to sign an informed consent before initiation of therapy after the nature of the study has been explained to them~* Females must be surgically sterile by hysterectomy or post menopausal~Exclusion Criteria:~* Subjects with no signs of inflammation or irritation of the skin on the forearms~* Subjects with prior history of actinic keratosis or skin cancer on the forearm~* Females of child bearing potential~* Subjects with any concurrent therapy (e.g., retinoids, fluorouracil) on the forearms that may interfere with clinical evaluations~* Subjects taking oral supplemental niacin, by itself or in the form of a multi-vitamin that exceeds 40 mg/day~* No known immunosuppression by virtue of medication or disease, including AIDS patients, subjects taking oral prednisone, and subjects on immunosuppressants/immunomodulators( cyclosporine, chemotherapeutic agents, or biologic therapy), determined by the examining investigator/co-investigator~* Uncontrolled intercurrent illness including, but not limited to any of ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Subjects who have had invasive cancer within the past 5 years~* Skin conditions felt by the study physician to contraindicate enrollment including, but not limited to, psoriasis or atopic dermatitis within a proposed treatment area~* Less than 30 days since prior and no concurrent or planned participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Myristyl (right), Placebo (Left) (Type: EXPERIMENTAL): Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo
- Myristyl (Left), Placebo (Right) (Type: EXPERIMENTAL): Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simultaneous TransPRK and Corneal Collagen Cross-Linking

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with progressive stage II or III keratoconus~* CDVA \< 0.00 logMAR or subjective problems with spectacle corrected visual quality (ghost images or light scatter symptoms)~Exclusion Criteria:~* Active ocular surface disease~* Minimum corneal thickness \<390µm (leaving 325µm residual stromal thickness after transPTK - in line with minimum thickness recommendations for the study CXL protocol)~* Vulnerable groups (patients whose capacity for giving informed consent to participate in the trial may be impaired)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- TransPRKCXL (Type: EXPERIMENTAL): Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
- CXL only (Type: ACTIVE_COMPARATOR): Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Subjects with CIMF (including post ET/PV MF) requiring therapy, including:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Men of reproductive potential who can agree to practice effective contraception during the entire study period and for one month after the last study treatment~* Women of child-bearing potential who have a negative pregnancy test within 14 days prior to the first dose of study drug and can agree to practice effective contraception during the entire study period and for one month after the last study treatment, unless documentation of infertility exists~* Subjects who are able to understand and willing to sign the informed consent form~Exclusion Criteria~* Subjects with uncontrolled inter-current illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as judged by treating physician. Subjects receiving antibiotics for infections that are under control may be included in the study unless the antibiotic is a CYP3A4 inducer/inhibitor~* Subjects known to be HIV-positive~* Subjects with known active hepatitis A, B, or C, or latent hepatitis B~* Women who are pregnant or lactating~* Subjects with prior radiation therapy to more than 20% of the hematopoietic marrow (prior radiation to spleen is allowed)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who is diagnosed as AA and refractory to immunosuppressive therapy~* Platelet ≤ 30,000/μL~Exclusion Criteria:~* Concurrent active infection not adequately responding to appropriate therapy~* HIV positivity~* Bone marrow reticulin grade of \> 1~* Clinically significant cardiac disease~* Arterial or venous thrombosis within the last 1 year before enrollment~* Other cause of thrombocytopenia~* AA with hemolytic predominant paroxysmal nocturnal hemoglobinuria (PNH)~* Uncontrolled diabetes~* Receiving any agent used to treat AA, including antithymocyte globulin (ATG) or ATG + cyclosporine within 6 months before starting study treatment and/or cyclosporine or anabolic hormone within 6 weeks before starting the study treatment~* History of PEG-rHuMGDF, recombinant human thrombopoietin, AMG531, and other thrombopoietin (TPO)-receptor agonist~* Who plans to conduct hematopoietic stem cell transplantation within 1 year

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG531 (Dose 1) (Type: EXPERIMENTAL): None
- AMG531 (Dose 2) (Type: EXPERIMENTAL): None
- AMG531 (Dose 3) (Type: EXPERIMENTAL): None
- AMG531 (Dose 4) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy caucasian subjects of both sexes between the ages of 24-35 years, who are able to spend one week on the Clinical \& Translational Research Center at the University of Pittsburgh Medical Center (UPMC) Montefiore~Exclusion Criteria:~* Pregnancy~* Any cardiac, renal, pulmonary, endocrine, musculoskeletal, hepatic, hematological, malignant or rheumatologic diseases~* Body mass index great than 30~* Anemia~* Significant alcohol or drug abuse~* Baseline hypotension or hypertension~* Abnormal screening labs~* Use of certain chronic medications excluding oral contraceptives~* Receiving an investigational drug in the last 90 days~* Previously receiving PTH or PTHrP~* African-American race

- Gender: ALL
- Minimum Age: 24 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- PTHrP(1-36) 2 pmol/kg/hr (Type: EXPERIMENTAL): PTHrP(1-36) at 2 picomoles/kg/hr for one week.
- PTHrP (1-36) 4 pmol/kg/hr (Type: EXPERIMENTAL): PTHrP(1-36) at 4 picomoles/kg/hr for one week.
- PTHrP(1-36) 5 pmol/kg/hr (Type: EXPERIMENTAL): PTHrP(1-36) at 5 picomoles/kg/hr for one week.
- PTHrP(1-36) 6 pmol/kg/hr (Type: EXPERIMENTAL): PTHrP(1-36) at 6 picomoles/kg/hr for one week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D for Sickle-cell Respiratory Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of sickle cell disease (HbSS, HbSC, HbS Beta-thalassemia)~* Age 3 to 20 years old~Exclusion Criteria:~* Patient (or parent or guardian) unwilling or unable to provide written informed consent (and assent, if applicable)~* Patient unable or unwilling to comply with requirements of the clinical trial~* Participation in other therapeutic clinical trial~* Current diagnosis of rickets~* History of hypercalcemia or diagnosis of any medical condition associated with hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis, tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia~* Current use of corticosteroids, excluding inhaled steroids~* Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine)~* Therapy with thiazide diuretics or lithium carbonate~* Known liver or renal disease~* Patients taking medications for pulmonary complications of sickle cell disease not on a stable dose of medications, as defined by a change in medications or doses within the three months prior to study entry~* Patients on chronic red blood cell transfusion therapy~* Absence of baseline record of respiratory events (respiratory infections, asthma exacerbations, episodes of acute chest syndrome) for the preceding year~* Pregnancy

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 100,000 IU (Type: EXPERIMENTAL): Oral vitamin D3, 100,000 IU \[2.5 mg\] given once a month
- Vitamin D3 12,000 IU (Type: ACTIVE_COMPARATOR): Standard dose oral vitamin D3 12,000 IU \[0.3 mg\] given once a month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Community-dwelling patients ≥ 18 years of age with incurable, histologically diagnosed cancer.~* Involuntary loss of body weight of ≥ 5 % within the past 6 months~Exclusion Criteria:~* Presently hospitalized or in a nursing care facility.~* Inability to increase food intake from secondary causes.~* Liver disease~* If female-pregnant, breast-feeding or of childbearing potential.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* In the dose-escalation phase: patients with advanced solid tumors refractory to standard treatment, intolerant of standard treatment, or for which no standard therapy exists.~In the dose-expansion phase: histologically- or cytologically-confirmed advanced or metastatic biliary tract cancer (BTC), esophagus cancer(EC) (squamous cell carcinoma) or squamous cell carcinoma of the head and neck (SCCHN). - men or women. - Eastern Cooperative Oncology Group (ECOG) status of 0 or 1. - Adequate organ and marrow function. - Subjects must have at least 1 measurable lesion. - Available archived tumor tissue sample. - Willingness to provide consent for biopsy samples.~Exclusion Criteria:~* Any prior Grade ≥ 3 irAE while receiving immunotherapy - Prior exposure to any anti-PD-1 or anti-PD-L1 antibody - Active or prior documented autoimmune disease within the past 2 years - History of primary immunodeficiency - Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment - Women who are pregnant or lactating - Uncontrolled intercurrent illness - Known history of tuberculosis - Known to be human immunodeficiency virus (HIV) positive - Hepatitis B or C infection - Other invasive malignancy within 5 years

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- MEDI4736 Q2W (Type: EXPERIMENTAL): Evaluate MEDI4736 given every 2 weeks
- MEDI4736 Q3W (Type: EXPERIMENTAL): Evaluate MEDI4736 given every 3 weeks
- MEDI4736 Dose Expansion (Type: EXPERIMENTAL): evaluate MEDI4736 given every 2 weeks
- MEDI4736 Q4W (Type: EXPERIMENTAL): Evaluate MEDI4736 given every 4 weeks
- MEDI4736 combined with another drug (Type: EXPERIMENTAL): evaluate MEDI4736 in combination with another drug given every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete